Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 401521
Title Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector
Author(s) Kortekaas, J.A.; Boer, S.M. de; Kant, J.; Vloet, R.P.M.; Antonis, A.F.G.; Moormann, R.J.M.
Source Vaccine 28 (2010)27. - ISSN 0264-410X - p. 4394 - 4401.
Department(s) CVI Virology
CVI - Division Virology
Publication type Refereed Article in a scientific journal
Publication year 2010
Keyword(s) newcastle-disease-virus - neutralizing antibodies - envelope glycoproteins - monoclonal-antibodies - respiratory-tract - lethal infection - avian influenza - protects mice - saudi-arabia - i interferon
Abstract Rift Valley fever virus (RVFV) causes recurrent large outbreaks among humans and livestock. Although the virus is currently confined to the African continent and the Arabian Peninsula, there is a growing concern for RVFV incursions into countries with immunologically naive populations. The RVFV structural glycoproteins Gn and Cc are preferred targets in the development of subunit vaccines that can be used to control future outbreaks. We here report the production of Gn and Cc by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and demonstrate that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice. We also demonstrate that a single intramuscular vaccination of lambs, the main target species of RVFV, is sufficient to elicit a neutralizing antibody response. (C) 2010 Elsevier Ltd. All rights reserved.
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.